Table 7.
Hazard ratios of high- and low-dose statin use
| Outcome | Hazard ratio (95% CI) | Number of subjects |
|---|---|---|
| Survival | ||
| Low-dose | 0.74 (0.69–0.79) | 6651 |
| High-dose | 0.71 (0.62–0.82) | 888 |
| No statin | 1.00 [reference] | 12,168 |
| High-dose versus low-dose | 0.97 (0.84–1.11) | – |
| All-cause rehospitalization | ||
| Low-dose | 0.89 (0.85–0.94) | 4993 |
| High-dose | 0.91 (0.82–1.00) | 679 |
| No statin | 1.00 [reference] | 14,035 |
| High-dose versus low-dose | 1.01 (0.92–1.12) | – |
| Cardiovascular events | ||
| Low-dose | 0.94 (0.85–1.03) | 6310 |
| High-dose | 1.10 (0.94–1.29) | 815 |
| No statin | 1.00 [reference] | 12,582 |
| High-dose versus low-dose | 1.18 (1.02–1.37) | – |
CI, confidence interval.
A total of 888 patients used high-dose statin before death occurred or the end of the follow-up period; 679 patients used high-dose statin before re-hospitalization after discharge from the index hospitalization or the end of the follow-up period; and 815 patients used high-dose statin before a cardiovascular event occurred or the end of the follow-up period.